

is used during pregnancy, it should be discontinued (time period to be supplied by manufacturer) before the expected delivery date.

PRECAUTIONS

Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Particularly susceptible are elderly patients, patients with impaired hepatic or renal function, patients who are debilitated or malnourished, and patients with adrenal or pituitary insufficiency. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, or when more than one glucose-lowering drug is used.

(To be inserted for chlorpropamide only:) Because of the long half-life of chlorpropamide, patients who become hypoglycemic during therapy require careful supervision of the dose for at least 3 to 5 days, during which time frequent feedings are essential. It may be necessary to hospitalize such patients and give intravenous glucose.

Certain drugs may potentiate the hypoglycemic action of (drug), including phenylbutazone, oxyphenbutazone, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. See ACTIONS.